Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions - A debate: Pro

Current Treatment Options in Gastroenterology

Volumn 10, Issue 4, 2007, Pages 294-304

  Navarro Rodriquez, Tomás ^b   Fass, Ronnie ^a  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

CLINICAL EVALUATION; DISEASE SEVERITY; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HEARTBURN; HEREDITY; HUMAN; LIFESTYLE MODIFICATION; PATHOGENESIS; PHENOTYPE; PROGNOSIS; QUALITY OF LIFE; REFLUX ESOPHAGITIS; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 34547595172     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0072-5     Document Type: Review

References (56)

1. Spechler S, Goyal R: Barrett's esophagus. N Engl J Med 1986, 315:362-371.
2. Labenz J, Jaspersen D, Kulig M, et al.: Risk factors for erosive esophagitis: a multivariate analysis based on the proGERD study initiative. Am J Gastroenterol 2004, 99:1652-1656.
3. Fass R, Ofman J: Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol 2002, 97:1901-1909.
4. Fass R: Gastroesophageal reflux disease revisited. Gastroenterol Clin North Am 2002, 31:S1-S10.
5. Fass R: Distinct phenotypic presentations of gastroesophageal reflux disease: a new view of the natural history. Dig Dis 2004, 22:100-107.
6. Pace F, Bianchi Porro G: Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol 2004, 99:946-949.
7. Quigley E: Non-erosive reflux disease: a part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 2001, 13(Suppl 1):S13-S18.
8. Agrawal A, Castell D. GERD is chronic but not progressive [editorial]. J Clin Gastroenterol 2006, 40:374-375.
9. Kaltenbach T, Crockett S, Gerson L: Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006, 166:965-971.
10. Hanna S, Rastogi A, Weston A, et al.: Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol 2006, 101:1416-1420.
11. Pace F, Bollani S, Molteni P, Bianchi Porto G: Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD) - a reappraisal 10 years on. Dig Liver Dis 2004, 36:111-115.
12. Pace F, Pallotta S, Molteni P, et al.: Natural history of NERD in 3 Italian tertiary referral centres after 5 years of follow-up [abstract]. Gut 2006, 55(Suppl 5):A62.
13. Shapiro M, Green C, Faybush E, et al.: The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups. Aliment Pharmacol Ther 2006, 23:321-329.
14. Fass R: Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007, 41:131-137.
15. Klinkenberg-Knol E, Castell D: Clinical spectrum and diagnosis of gastroesophageal reflux disease. In The Esophagus, edn 2. Edited by Castell D, Richter J. Philadelphia: Lippincott Williams & Wilkins; 1999:435-442.
16. Lind T, Havelund T, Carlsson R, et al.: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997, 32:974-979.
17. Fass R, Fennerty M, Vakil N: Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 2001, 96:303-314.
18. Schenk B, Kuipers E, Klinkenberg-Knol E: Omeprazole as a diagnostic tool in gastroesophageal. reflux disease. Am J Gastroenterol 1997, 92:1997-2000.
19. Johnsson F, Weywadt L, Solhaug J, et al.: One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998, 33:15-20.
20. Fass R, Ofman J, Gralnek I, et al.: Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999, 159:2161-2168.
21. Fass R, Tougas G: Functional heartburn: the stimulus, the pain, and the brain. Gut 2002, 51:885-892.
22. Hobson A, Matthews P, Furlong P, Aziz Q: The role of esophageal afferent pathway sensitivity in non-erosive reflux disease [abstract]. Gastroenterology 2004, 126:128.
23. Young M, Li ZS, Xu XR, et al.: Characterization of cortical potentials evoked by esophageal balloon distention and acid perfusion in patients with functional heartburn. Neurogastroenterol Motil 2006, 18:292-299.
24. Rodriguez-Stanley S, Robinson M, Earnest D, et al.: Esophageal hypersensitivity may be a major cause of heartburn. Am J Gastroenterol 1999, 94:628-631.
25. Shapiro M, Green C, Bautista J, et al.: Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol 2006, 101:1084-1091.
26. Frazzoni M, De Micheli E, Zentilin P, Savarino V. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004, 20:81-88.
27. Martinez SD, Malagon IB, Garewal HS, et al.: Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003, 17:537-545.
28. Cicala M, Emerenziani S, Caviglia R, et al.: Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003, 18:605-613.
29. Prakash C, Clouse R: Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2005, 3:329-334.
30. Lee YC, Wang HP, Chiu HM, et al.: Patients with functional heartburn are more likely to report retrosternal discomfort during wireless pH monitoring. Gastrointest Endosc 2005, 62:834-841.
31. Caviglia R, Ribolsi M, Maggiano N, et al.: Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 2005, 100:543-548.
32. Schindlbeck N, Wiebecke B, Klauser A, et al.: Diagnostic value of histology in non-erosive gastrooesophageal reflux disease. Gut 1996, 39:151-154.
33. Pace F, Santalucia F, Bianchi Porro G: Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut 1991, 32:845-848.
34. Kuster E, Ros E, Toledo-Pimentel V, et al.: Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut 1994, 35:8-14.
35. Isolauri J, Luostarinen M, Isolauri E, et al.: Natural course of gastroesophageal reflux disease: 17-22 year follow-up of patients. Am J Gastroenterol 1997, 92:37-41.
36. McDougall N, Johnston B, Kee F, et al.: Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996, 38:481-486.
37. McDougall N, Johnston B, Collins J, et al.: Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol 1997, 9:1161-1167.
38. Manabe N, Yoshihara M, Sasaki A, et al.: Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol 2002, 17:949-954.
39. Labenz J, Nocon M, Lind T, et al.: Prospective follow-up data from the ProGERD study suggest that GERD is not a categorical disease. Am J Gastroenterol 2006, 101:2457-2462.
40. Willich S, Nocon M, Kulig M, et al.: Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosa. Aliment Pharmacol Ther 2006, 23:371-376.
41. Garrido Serrano A, Guerrero Igea FJ, Lepe Jiménez JA, Perianes Hernández C: Clinical features and endoscopic progression of gastroesophageal reflux disease. Rev Esp Enferm Dig 2003, 95:712-716.
42. Sontag S, Sonnenberg A, Schnell T, et al.: The long-term natural history of gastroesophageal reflux disease. J Clin Gastroenterol 2006, 40:398-404.
43. Bardhan KD, Royston C, Nayyar AK: Reflux rising! An essay on witnessing a disease in evolution. Dig Liver Dis 2006, 38:163-168
44. Cameron A, Lagergren J, Henriksson C, et al.: Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002, 122:55-59.
45. Romero Y, Cameron A, Locke G, 3rd, et al.: Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 1997, 113:1449-1456.
46. Quigley E: Factors that influence therapeutic outcomes in symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003, 98(3 Suppl):S24-S30.
47. Castell D, Kahrilas P, Richter J, et al.: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002, 97:575-583.
48. Hetzel D, Dent J, Reed W, et al.: Heating and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988, 95:903-912.
49. Sifrim D, Holloway R, Silny J, et al.: Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001, 120:1588-1598.
50. Fass R, Naliboff B, Higa L, et al.: Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1988, 115:1363-1373.
51. Vela M, Camacho-Lobato L, Srinivasan R, et al.: Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001, 120:1599-1606.
52. Wiklund I, Bardhan K, Muller-Lissner S, et al.: Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol 1998, 30:19-27.
53. Stalhammer N, Carlsson J, Peacock R, et al.: Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. Pharmacoeconomics 1999, 16:483-497.
54. Gerson L, Robbins A, Garbert A, et al.: A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Gastroenterology 2000, 95:395-407.
55. Galmiche JP, Barthelemy P, Hamelin B: Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997, 11:765-773.
56. Dean B, Gano A, Jr, Knight K, et al.: Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004, 2:656-664.